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Determination of lidocaine and its two N-desethylated metabolites in dog
and horse plasma by high-performance liquid chromatography combined
with electrospray ionization tandem mass spectrometry
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bstract
A sensitive method for the quantification of lidocaine and its metabolites, monoethylglycinexylidide (MEGX) and glycinexylidide (GX), in
nimal plasma using high-performance liquid chromatography combined with electrospray ionization mass spectrometry is described. The sample
reparation includes a liquid–liquid extraction with methyl tert-butylmethyl ether after addition of 2 M sodium hydroxide. Ethylmethylglycinexy-
idide (EMGX) is used as an internal standard. For chromatographic separation, an ODS Hypersil column was used. Isocratic elution was achieved
ith 0.01 M ammonium acetate and acetonitrile as mobile phases. Good linearity was observed in the range of 2.5–1000 ng ml−1 for lidocaine
n both dog and horse plasma. For MEGX, linear calibration curves were obtained in the range of 5–1000 ng ml−1 and 20–1000 ng ml−1 for dog
nd horse plasma, respectively. In dog and horse plasma good linearity was observed in the range of 200–1500 ng ml−1 for GX. The limit of
uantification (LOQ) in dog plasma for lidocaine, MEGX and GX was set at 2.5 ng ml−1, 20 ng ml−1 and 200 ng ml−1, respectively. For horse
lasma a limit of quantification of 2.5 ng ml−1, 5 ng ml−1 and 200 ng ml−1 was achieved for lidocaine, MEGX and GX, respectively. In dog plasma,
−1 −1 −1he limit of detection (LOD) was found to be 0.8 ng ml , 2.3 ng ml and 55 ng ml for lidocaine, MEGX and GX, respectively. In horse plasma
he LOD’s found for lidocaine, MEGX and GX, were 1.1 ng ml−1, 0.5 ng ml−1 and 13 ng ml−1, respectively. The method was shown to be of use
n pharmacokinetic studies after application of a transdermal patch in dogs and after an intravenous infusion in horses.
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. Introduction
Lidocaine is an aminoethylamide local anaesthetic drug.
he clinical application of intravenous lidocaine for the treat-
ent of acute postoperative pain in people and animals was
eported more than 40 years ago [1,2]. Besides the use as
ocal anaesthetic drug, lidocaine is also indicated for short-
erm emergency control of ventricular arrythmias [3]. The
rug is extensively used topically for treatment of posther-
etic neuralgia and other peripheral pain syndromes in men.
∗ Corresponding author. Tel.: +32 9 264 73 24; fax: +32 9 264 74 97.
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oi:10.1016/j.jchromb.2007.01.010tography/electrospray ionization tandem mass spectrometry; Quantification;
ransdermal drug delivery systems offer thereby specific ben-
fits, such as almost no side effects which may be induced
y systemic uptake. Since transdermal systems have minimal
ystemic absorption, it is expected that plasma concentrations
re very low. Until now, only one study has been performed
bout the use of a transdermal lidocaine patch in animals
dogs) [4].
The two main de-ethylated metabolites of lidocaine are
onoethylglycinexylidide (MEGX) and glycinexylidide (GX)
5]. These two metabolites have similar pharmacological and
oxicological actions, being however less potent than lidocaine.
n order to study the pharmacokinetic properties of lidocaine
nd its two metabolites in plasma, there is a need for highly
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al drug delivery where low plasma concentrations can be
xpected.
A few procedures for the determination of lidocaine and
etabolites in plasma using high-performance liquid chro-
atography with UV detection have been described [6–10].
he limit of quantification (LOQ) ranged from 50 ng ml−1 to
00 ng ml−1. Fukuda et al. [6,7] only mentioned the limit of
etection (LOD), which ranged from 10 ng ml−1 to 20 ng ml−1.
With the introduction of LC–MS, very low LOQ’s for lido-
aine in human plasma, ranging from 0.2 ng ml−1 to 2.5 ng ml−1,
ave been achieved [11–13]. However, only one of these meth-
ds was developed to determine lidocaine in animal (rat) plasma,
ut without simultaneous quantification of its metabolites [11].
o our knowledge, the method published by Abdel-Rehim et al.
as the first LC–MS/MS method reported for the simultaneous
etermination of lidocaine and its metabolites in human plasma
nd urine. For the sample clean-up an ultrafiltration step was
erformed and a triple quadrupole MS instrument was used for
etection. The LOQ’s described were 0.4 ng ml−1 for lidocaine,
EGX and GX [14].
The purpose of our study was to develop an LC–MS/MS
ethod using an ion trap instrument for the simultaneous deter-




The dog plasma samples originated from six beagle dogs that
ere treated with a lidocaine patch containing 5% of lidocaine
700 mg/patch, Neurodol® Tissugel; IBSA, Lugano, Switzer-
and) [4]. The horse plasma samples originated from six horses
hat received an intravenous infusion of lidocaine, at a loading
ose of 0.13 mg kg−1 min−1 for 10 min and a maintenance dose
f 0.05 mg kg−1 min−1 for 110 min.
.2. Chemicals and standards
Lidocaine, its metabolites monoethylglycinexylidide
MEGX) and glycinexylidide (GX), and the internal stan-
ard ethylmethylglycinexylidide (EMGX) were donated by
straZeneca (So¨derta¨lje, Sweden). The structures of these
nalytes are shown in Fig. 1. HPLC grade water, methanol
nd acetonitrile were obtained from Acros (Geel, Belgium).
mmonium acetate and tert-butylmethyl ether were delivered
y Sigma–Aldrich (Bornem, Belgium). Sodium hydroxide was
urchased from Merck (Brussels, Belgium).
.3. Instruments and methods
The LC–MS/MS analyses were performed using a Sur-
eyor LC system consisting of a quaternary pump with vacuum
egasser, an autosampler with cooling device and a LCQ
dvantage® ion trap mass spectrometer equipped with an ESI
ource (all from Thermo Finnigan, San Jose, USA), run by
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For chromatographic separation, an ODS Hypersil column
5m, 100 mm × 3.0 mm i.d.) from Thermo Finnigan with a
uard column of the same type (5m, 10 mm × 3.0 mm i.d.)
as used. An isocratic run of 6 min was performed with a mobile
hase of 0.01 M ammonium acetate in water/acetonitrile (40/60,
/v) at a flow rate of 0.2 ml min−1. After each isocratic run the
olumn was washed with 100% acetonitrile during 2 min and
econditioned for 10 min with the same mobile phase as the
socratic run.
Operating conditions for the ESI source, used in the pos-
tive ionization mode, were optimized by constantly adding
mixture of lidocaine, its metabolites and EMGX, each at a
oncentration of 10g ml−1 in water/methanol (50/50, v/v), to
he HPLC flow by a syringe pump via a T connector in the
nfusion mode. The following tune parameters were obtained
or optimal lidocaine detection: spray voltage, 4.5 kV; sheath
as flow-rate, 60 (arbitrary units); auxiliary gas flow-rate, 10
arbitrary units); capillary voltage, 3.0 V; capillary temperature,
30 ◦C; tube lens offset, 30 V; octapole 1 offset, −1.5 V; lens
oltage, −7.0 V; octapole 2 offset, −6.0 V and octapole r.f.
mplitude, 400 Vp-p. These tune parameters were also suitable
or detection of GX, MEGX and EMGX, given the structural
imilarity between these components. The optimal collision
nergy in the MS/MS mode, corresponding to nearly 100% frag-
entation of the protonated molecular ion of lidocaine (m/z
35 for Mr of 234.34), was found to be 1.9 V. For MEGX
m/z 207 for Mr of 206.29) the optimal collision energy was
etermined at 1.6 V and at 1.8 V for GX (m/z 179 for Mr of
78.24). Under these conditions, most abundant product ions
t m/z 86, 58 and 122 were obtained for lidocaine, MEGX and
X, respectively. The optimal collision energy for EMGX (m/z
21 for Mr of 220.32) was determined at 1.7 V and m/z 72 was
ound to be the most abundant product ion. Quantification was
ffected with the LCQuan software, using the above-mentioned
roduct ions.
.4. Extraction method
.4.1. Calibration curve and quality control samples
Stock solutions of lidocaine, MEGX, GX and EMGX of
00g ml−1 were prepared in methanol and stored at −20 ◦C.
he stock solutions of lidocaine, MEGX and GX were combined
nd diluted with methanol/water (50/50, v/v) to obtain working
olutions containing 0.025g ml−1, 0.05g ml−1, 0.2g ml−1,
.5g ml−1, 1.0g ml−1, 2.5g ml−1, 5.0g ml−1 and
0g ml−1 lidocaine, MEGX and GX. By adding 100l of
hese working solutions or 100l methanol/water (50/50, v/v)
o 900l of plasma, lidocaine, MEGX and GX concentrations
f 2.5 ng ml−1, 5 ng ml−1, 20 ng ml−1, 50 ng ml−1, 100 ng ml−1,
50 ng ml−1, 500 ng ml−1, 1000 ng ml−1 and 0 ng ml−1 in
lasma, respectively, were obtained. All the working solutions
ere stored in a refrigerator (2–8 ◦C). The stock solution of
he internal standard was also diluted in methanol/water (50/50,
/v) to a final concentration of 10g ml−1. Quality control (QC)
amples were prepared in a similar way using the working solu-
ion of 0.5g ml−1 and 2.5g ml−1, yielding a concentration of
0 ng ml−1 and 250 ng ml−1 of each analyte. For the analysis of























2ig. 1. Structure, MS and MS/MS spectra of lidocaine, MEGX, GX and EMG
EGX, GX and EMGX (ESI positive mode, collision energy in MS/MS = 1.9 V
og plasma, QC samples containing only 250 ng ml−1 of each
nalyte were prepared.
.4.2. Sample preparation
A 1000l plasma sample was transferred into an extrac-
ion tube. All plasma samples, including calibration standards
nd quality control samples, were spiked with 100l of the
iluted internal standard (10g ml−1), except for the blanks. To
ll samples 250l of 2 M sodium hydroxide was added. After
ortex mixing for 15 s, 5 ml tert-butylmetyl ether was added.
he tubes were placed on a horizontal roller and rotated for
0 min. The samples were then centrifugated at 1800 × g for
0 min. The organic layer was transferred in another extraction
ube and evaporated at 40 ◦C under a gentle nitrogen stream.
he dry residue was dissolved in 250l of 0.01 M ammo-
ium acetate/acetonitrile (50/50, v/v). An aliquot of 100l was
njected.. Validation procedure
The proposed method for the quantitative determination of
idocaine and metabolites was validated by a set of parametersbtained after direct infusion of standard solutions of 10g ml−1 of lidocaine,
V, 1.6 V and 1.7 V for lidocaine, MEGX, GX and EMGX, respectively).
hich are in compliance with the recommendations as defined
y the EC [15–18]:
. Linearity: determined on calibration curves using spiked
blank plasma samples (for levels, see Section 2.4.1).
Peak area ratios between lidocaine, MEGX or GX and
EMGX were plotted against their concentration and a lin-
ear regression was performed. The acceptance criterion was
a correlation coefficient r≥ 0.99 and a goodness-of-fit coef-
ficient g≤ 20% for lidocaine and MEGX and g≤ 10% for
GX.
. Trueness: determined by analyzing six independently spiked
blank plasma samples at the same spike level. For dog plasma
these levels were 20 ng ml−1 and 500 ng ml−1 for lidocaine,
50 ng ml−1 and 100 ng ml−1 for MEGX and 500 ng ml−1
and 1000 ng ml−1 for GX. In horse plasma spike levels
of 5 ng ml−1 and 25 ng ml−1 for lidocaine, 25 ng ml−1 and
500 ng ml−1 for MEGX and 250 ng ml−1 and 500 ng ml−1
for GX were used. The trueness, expressed as the difference
between the mean found concentration and the spiked con-
centration, should be in the range of −30% to +10% for levels
≤10 ng ml−1 and −20% to +10% for levels >10 ng ml−1.
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Fig. 2. Possible fragmentation scheme for lidocaine, MEGX, GX and EMGX based on the data published by Dal Bo et al. [13].
Fig. 3. Extracted-ion chromatogram of lidocaine (A), MEGX (B), GX (C) and EMGX (D) for a blank dog plasma sample (left), a blank dog plasma sample spiked
at 50 ng ml−1 of lidocaine and MEGX and at 500 ng ml−1 and 1000 ng ml−1 for GX and EMGX, respectively (middle), and an incurred dog plasma sample at
25.1 ng ml−1 and 5.9 ng ml−1 of lidocaine and MEGX, respectively (right). No GX was detected.

















rig. 4. Calibration curve of lidocaine (left) and MEGX (right) in dog plasma rep
ach individual calibration curve being a new set of extractions.
. Precision: expressed as the relative standard deviation (RSD,
%), being the ratio between the standard deviation (SD)
and the mean found concentration. For the within-day
precision, the RSD should be lower than the values cal-
culated according to two-thirds of the Horwitz equation:
RSDmax = 2/3 × 2(1−0.5 log C), with C being the concentration
at which the sample is fortified. It is determined using the
same samples as for the trueness.
The between-day precision was evaluated using samples
with the same spike levels, but prepared and analyzed on
different days. Dog plasma samples were fortified with
50 ng ml−1 and 250 ng ml−1. For horse plasma only levels
at 50 ng ml−1 were used. The RSD should be lower than the
RSDmax = 2(1−0.5 log C).
. Limit of quantification (LOQ): determined as the lowest con-
centration for which the method is validated with a trueness
and precision that fall within the ranges recommended by the
EU.
. Limit of detection (LOD): determined as the lowest mea-
sured content from which it is possible to deduce the presence
of the analyte with reasonable statistical certainty, using the
criterion of a signal-to-noise (S/N) ratio of 3/1.
. Ion suppression: for the study of the ion suppression a post-




Dted as the mean of six calibration curves constructed over a period of 144 days,
was injected onto the LC–MS instrument. A standard solution
containing lidocaine, MEGX, GX and EMGX was continu-
ously infused through a T-coupling device into the LC eluate.
This allowed to visualize sections in the chromatogram where
ion suppression occurs.
. Results and discussion
.1. Mass spectrometry
The structures of lidocaine, MEGX, GX and EMGX
re shown in Fig. 1, together with their MS and MS/MS
races, obtained after direct infusion of a standard solution of
0g ml−1 in the ESI source operating in positive ion mode. In
egative mode no signal was obtained. All publications found
or the determination of lidocaine with LC–MS/MS also used
he ESI source in positive mode [11–14]. In the MS mode the
recursor ion for lidocaine, MEGX, GX and EMGX is the pro-
onated molecular ion [M + H]+ at m/z 235, 207, 179 and 221,
espectively. In the MS/MS mode the most intense product ion
s at m/z 86, 58, 122 and 72 for lidocaine, MEGX, GX and
MGX, respectively. A possible fragmentation scheme is pre-
ented in Fig. 2, based on the data for lidocaine published by
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.2. Sample preparation and chromatography
The chromatographic and extraction method was based on
he method of Dal Bo et al. [13]. For chromatographic separa-
ion several columns were evaluated, i.e. Nucleosil C18 (Varian,
00 mm × 3.0 mm), ODS Persuit (Varian, 100 mm × 3.0 mm)
nd PRLP-S (Polymer Laboratories, 150 mm × 2.1 mm). These
olumns all gave broad peaks with poor peak shapes. The Hyper-
il ODS column (Thermo Finnigan, 100 mm × 3.0 mm) was
hosen because acceptable peak shapes and retention times for
ll four components were obtained.
For the extraction method the organic layer of the samples was
ot frozen as described by Dal Bo et al., but was centrifugated
onger and at a higher g-force. This was sufficient to obtain
good separation between the organic layer and plasma. Using
his method, the organic layer was directly evaporated to dryness
nstead of performing a back-extraction using 17 mM H3PO4
olution. By evaporating the organic layer, the dry residue could
y redissolved in the mobile phase, which was essential to obtain
ptimal chromatography. This method is straightforward and
ess time consuming since no back-extraction was performed.
Fig. 3 shows the extracted-ion chromatograms of lidocaine,





esults of the trueness, within-day and between-day precision evaluation experiment
og plasma Lidocaine (ng ml−1) MEGX (ng m
2.5 20 500 20
ithin-day (n) 6 6 6 6
verage 2.7 18.7 488.3 20.8
SD (%) 25.7 5.5 9.3 6.6
SDmax (%) 26.3 19.2 11.8 19.2
rueness (%) +7.8 −6.7 −2.3 +3.9
og plasma Lidocaine (ng ml−1) MEGX (ng m
50 250 50
etween-day (n) 12 12 10
verage 51.0 246.2 51.3
SD (%) 5.9 8.2 5.7
SDmax (%) 25.1 19.7 25.1
rueness (%) +1.9 −1.5 +2.6
orse plasma Lidocaine (ng ml−1) MEGX (ng m
2.5 5.0 25 5.0
ithin-day (n) 6 6 6 6
verage 2.4 5.1 25.0 5.1
SD (%) 8.3 7.4 6.4 11.3
SDmax (%) 26.3 23.7 18.6 23.7
rueness (%) −4.9 1.5 −0.1 2.8
orse plasma Lidocaine (ng ml−1) MEGX (ng m
50 50
etween-day (n) 10 7
verage 50.5 49.9
SD (%) 9.2 10.2
SDmax (%) 25.1 25.1
rueness (%) 0.9 −0.3. B 852 (2007) 180–187 185
lank dog plasma sample fortified at 50 ng ml−1 for lidocaine
nd MEGX and at 500 ng ml−1 and 1000 ng ml−1 for GX and
MGX, respectively, and an incurred dog plasma sample con-
aining 25 ng ml−1 and 5.9 ng ml−1 of lidocaine and MEGX,
espectively. No GX was detected.
The blank plasma sample shown in Fig. 3 demonstrates that
here are no interferences of endogenous components at the
lution time zones of all four components.
.3. Method validation
For the calibration curves good linearity was observed up to
000 ng ml−1 for both dog and horse plasma. The goodness-of-
t coefficients (g) of the individual calibration curves were all
10.94% and the correlation coefficients (r) all >0.9938. In Fig. 4
he calibration curve of lidocaine and MEGX in dog plasma is
resented as the mean of six calibration curves made over a
eriod of 144 days, each calibration curve originating from a
ew set of extractions.The results of the trueness and precision evaluation are sum-
arized in Table 1. The trueness fell within the range of −30%
nd +10% for concentrations ≤10 ng ml−1 and within −20%
nd +10% for levels >10 ng ml−1, testifying the good trueness
s for dog and horse plasma
l−1) GX (ng ml−1)
50 100 200 500 1000
6 6 6 6 6
52.7 102.2 209.3 436.0 914.2
9.2 6.2 7.6 4.5 6.2
16.7 15.1 13.6 11.8 10.7








l−1) GX (ng ml−1)
25 500 200 250 500
6 6 6 6 4
24.6 470.6 191.7 273.2 486.9
8.1 11.3 11.3 1.8 9.0
18.6 11.8 13.6 13.1 11.8
−1.7 −5.9 −4.1 +9.3 −2.6
l−1)




































5ig. 5. Plasma concentrations of lidocaine () and MEGX () in a dog treat
ntravenous infusion (right).
f the method. The precision also fell within the maximum RSD
alues.
The LOQ was established by analyzing six blank plasma sam-
les, which were spiked with lidocaine at a level of 2.5 ng ml−1
or both dog and horse plasma, with MEGX at a level of
ng ml−1 and 20 ng ml−1 for horse and dog plasma, respec-
ively, and with GX at 200 ng ml−1 for both dog and horse
lasma. The results are summarized in Table 1. Since these lev-
ls could be quantified fulfilling the criteria for trueness and
recision, they were set as the LOQ for lidocaine, MEGX and
X, respectively.
The mean S/N ratio for the six LOQ samples was used to
alculate the LOD, which was 0.8 ng ml−1, 2.3 ng ml−1 and
5 ng ml−1 for lidocaine, MEGX and GX, respectively, in dog
lasma. For horse plasma the calculated LOD was 1.1 ng ml−1,
.5 ng ml−1 and 13 ng ml−1 for lidocaine, MEGX and GX,
espectively.
No ion suppression was noticed at the elution time zones of
ll four analytes in either dog or horse plasma.
.4. Analysis of biological samplesThe above described method for the quantitation of lidocaine
nd metabolites in dog plasma was used in a pharmacokinetic




wth a single lidocaine patch 5% for 12 h (left) and in a horse that received an
ix dogs. Lidocaine concentrations varied from 2.8 ng ml−1 to
55.4 ng ml−1.
Another pharmacokinetic study was performed in six
orses after intravenous infusion. Plasma concentrations ranged
rom 4.6 ng ml−1 to 1956.3 ng ml−1 and from 10.8 ng ml−1
o 490.6 ng ml−1 for lidocaine and MEGX, respectively, in
amples collected between 1 min and 14 h after start of the
dministration.
A representative plasma concentration versus time profile in
ne dog and one horse is shown in Fig. 5.
Moreover, to demonstrate further the practicability and appli-
ability of the LC–MS/MS method, the following data can be
entioned. The total number of unknown incurred dog plasma
nd horse plasma samples was 168 and 189, respectively. The
umber of spiked samples analyzed was 72 and 24 for dog and
orse plasma, respectively. All samples were analyzed using the
ame HPLC column.
. Conclusion
The method described in this paper for the quantitation
f lidocaine, MEGX and GX is a fast procedure. The min-
mal sample preparation, namely a liquid–liquid extraction,
llows the extraction of many samples a day. This method















[17] J. Knecht, G. Stork, Fresen. Z. Anal. Chem. 270 (2) (1974) 97.A. Maes et al. / J. Chrom
lasma during various pharmacokinetic studies. The LOQ’s
f the method made it possible to quantify low plasma con-
entrations, which is especially of use after transdermal drug
elivery and to characterize the terminal elimination phase of the
ompounds.
eferences
[1] E.E. Bartlett, Q. Hutaserani, J. Am. Med. Womens Assoc. 17 (1962)
809.
[2] A. Valverde, T.J. Doherty, J. Hernandez, W. Davies, Vet. Anaesth. Analg.
31 (2004) 264.
[3] J.R. Wilcke, L.E. Davis, C.A. Neff-Davis, J. Vet. Pharmacol. Ther. 6 (1983)
105.
[4] L. Weiland, S. Croubels, K. Baert, I. Polis, P. De Backer, F. Gasthuys, J.
Vet. Med. A 53 (2006) 34.
[5] R. Orlando, P. Piccoli, S. De Martin, R. Padrini, P. Palatini, Br. J. Clin.
Pharmacol. 55 (2003) 86.
[6] T. Fukuda, Y. Kakiuchi, M. Miyabe, N. Okubo, Y. Yaguchi, Y. Kohda, H.
Toyooka, Reg. Anesth. Pain. Med. 25 (2000) 268.
[7] T. Fukuda, Y. Kakiuchi, M. Miyabe, N. Okubo, Y. Yaguchi, Y. Kohda, H.
Toyooka, Reg. Anesth. Pain. Med. 28 (2003) 215.
[. B 852 (2007) 180–187 187
[8] P.K. Narang, W.G. Crouthamel, N.H. Carliner, M.L. Fisher, Clin. Pharma-
col. Ther. 24 (1978) 654.
[9] C.A. Neff-Davis, J.C. Wilcke, L.E. Davis, J. Vet. Pharmacol. Therap. 5
(1982) 289.
10] J.R. Wilcke, L.E. Davis, C.A. Neff-Davis, G.D. Koritz, J. Vet. Pharmacol.
Therap. 6 (1983) 49.
11] S. Kawano, H. Murakita, E. Yamamoto, N. Asakawa, J. Chromatogr. B 792
(2003) 49.
12] A.R. Gammaitoni, M.W. Davis, Ann. Pharmacother. 36 (2002) 236.
13] L. Dal Bo, P. Mazzucchelli, A. Marzo, J. Chromatogr. A 854 (1999) 3.
14] M. Abdel-Rehim, M. Bielenstein, Y. Askemark, N. Tyrefors, T. Arvidsson,
J. Chromatogr. B 741 (2000) 175.
15] Anonymous, Commission Decision (2002/657/EC) of 17 august 2002
implementing Council Directive 96/23/EC concerning the performance of
analytical methods and the interpretation of results, Off. J. Eur. Commun.
No. L221 (2002) 8.
16] R.J. Heitzman, Veterinary Drug Residues, Report Eur. 15127-EN, Com-
mission of the EC, Brussels, Luxembourg, 1994.18] Notice to applicants and Guideline. Veterinary medical products. Establish-
ment of maximum residue limits (MRLs) for residues of veterinary products
in foodstuffs of animal origin, volume 8 in the series “Rules governing
medicinal products in the European Union”, October 2005.
